Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows: - sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment; - sales of licenses (7.4%). At the end of 2021, the group had 3 production sites located in Japan (2) and China. Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).

Employees

5,974

Sector

Pharmaceuticals

Calendar

26/12/2024 - Final dividend

More about the company

Quotes

Date	Price	Change	Volume
12/12/24	2,456.50 ¥	-0.30%	1,205,900
11/12/24	2,464.00 ¥	-0.77%	1,068,700
10/12/24	2,483.00 ¥	-1.00%	970,200
09/12/24	2,508.00 ¥	+2.03%	1,349,400
06/12/24	2,458.00 ¥	+0.59%	1,115,300

Delayed Quote Japan Exchange, December 12, 2024 at 06:30 am

More quotes

Income Statement and Estimates

income-statement-evolution-chart KYOWA-KIRIN-CO-LTD

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2,464.00JPY

Average target price

3,057.69JPY

Spread / Average Target

+24.09%

Consensus

Profit revisions

estimates-change-chart KYOWA-KIRIN-CO-LTD

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart KYOWA-KIRIN-CO-LTD

Company calendar

Market Closed - Japan Exchange Other stock markets 06:30:00 12/12/2024 GMT			5-day change	1st Jan Change
2,456.50 ^JPY	-0.30%		+0.53%	+3.65%

12-10	Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies	CI
12-09	Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib At American Society of Hematology Annual Meeting	CI

Capitalization	1,254B 8.22B 7.84B 7.27B 6.45B 11.63B 697B 12.92B 90.35B 33.46B 287B 30.9B 30.21B	P/E ratio 2024 *	18.9x	P/E ratio 2025 *	18.1x
Enterprise value	937B 6.14B 5.86B 5.43B 4.82B 8.69B 521B 9.65B 67.49B 24.99B 214B 23.08B 22.57B	EV / Sales 2024 *	1.91x	EV / Sales 2025 *	1.81x
Free-Float	-	Yield 2024 *	2.35%	Yield 2025 *	2.41%

Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies	12-10	CI
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib At American Society of Hematology Annual Meeting	12-09	CI
Jefferies Adjusts Kyowa Kirin's Price Target to 3,000 Yen From 3,700 Yen, Keeps at Buy	11-22	MT
Health Care Climbs After Novartis Earnings - Health Care Roundup	11-21	DJ
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy	11-20	RE
Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug	11-20	MT
Kura Oncology, Inc., Kyowa Kirin Co., Ltd. - Special Call	11-20
Kyowa Kirin's Attributable Profit Gains Over 4% in Nine Months to September	11-06	MT
Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025	10-31	CI
Kyowa Kirin Concludes Repurchase Program with 3.6 Billion Yen Buyback	10-11	MT
Tranche Update on Kyowa Kirin Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	10-11	CI
Kyowa Kirin Co., Ltd.'s Equity Buyback announced on February 7, 2024, has closed with 14,365,500 shares, representing 2.69% for ¥39,999.95 million.	10-09	CI
Kyowa Kirin Buys Back 696,400 Shares for 2.26 Billion Yen in September	10-03	MT

Jefferies Adjusts Kyowa Kirin's Price Target to 3,000 Yen From 3,700 Yen, Keeps at Buy	11-22	MT
Jefferies Adjusts Kyowa Kirin's Price Target to 3,700 Yen From 3000 Yen, Keeps at Buy	08-05	MT
Jefferies Adjusts Kyowa Kirin’s Price Target to 3,000 Yen From 3,600 Yen, Keeps at Buy	09/10/23	MT
Jefferies Adjusts Kyowa Kirin's Price Target to 3,600 Yen From 3,900 Yen, Keeps at Buy	30/03/23	MT

Kyowa Kirin Co. Ltd. Share Price

Equities

4151

JP3256000005

Pharmaceuticals

Valuation: Kyowa Kirin Co. Ltd.

Chart: Kyowa Kirin Co. Ltd.

Latest news: Kyowa Kirin Co. Ltd.

Analysts' recommendations: Kyowa Kirin Co. Ltd.

Press Releases: Kyowa Kirin Co. Ltd.

News in other languages: Kyowa Kirin Co. Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Kyowa Kirin Co. Ltd.

ETFs: Kyowa Kirin Co. Ltd.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting	12-09	AQ
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias	11-20	AQ
Kyowa Kirin : Announcement Regarding the Transfer of Sales from Kyowa Kirin to LEO Pharma Following the Termination of the Distribution and Co-Promotion Agreement for the Psoriasis Vulgaris Treatment "Dovobet® Ointment, Gel, and Foam” in Japan	11-01	PU
Kyowa Kirin : Consolidated Financial Summary (IFRS) Fiscal 2024 Third Quarter	10-31	PU
Kyowa Kirin : Results Presentation Fiscal 2024 Third Quarter	10-31	PU

Rally di quattro sedute del Nikkei si interrompe su prese profitto	09-25
DKSH erhält Auftrag von Kyowa Kirin aus Japan	08-02
EEUU aprueba la primera terapia de genes para niños con una rara enfermedad hereditaria	03-18
MÄRKTE ASIEN/Tokio sehr fest auf 34-Jahreshoch - Softbank mit Kurssprung	02-08
Kyowa Kirin schließt erfolgreich die Übernahme von Orchard Therapeutics ab, einem Weltmarktführer für Gentherapie bei seltenen Krankheiten	01-25

1 day	-0.30%
1 week	+0.53%
Current month	-1.19%
1 month	-5.86%
3 months	-25.04%
6 months	-8.78%
Current year	+3.65%

Director	Title	Age	Since
Masashi Miyamoto CEO	Chief Executive Officer	65	-
Motohiko Kawaguchi DFI	Director of Finance/CFO	-	31/03/1986
Takuo Hirose CTO	Chief Tech/Sci/R&D Officer	53	31/03/2019

Manager	Title	Age	Since
Toshifumi Mikayama BRD	Director/Board Member	67	28/02/2014
Masashi Miyamoto BRD	Director/Board Member	65	28/02/2018
Yutaka Osawa BRD	Director/Board Member	65	28/02/2018

Name	Weight	AuM	1st Jan change	Investor Rating
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY	2.22%	16 M€	+9.88%
GLOBAL X MSCI GOVERNANCE-QUALITY JAPAN ETF - JPY	0.44%	3 M€	+17.77%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
KYOWA KIRIN CO. LTD.	-0.30%	+0.53%	-0.08%	-23.71%	8.22B
MERCK KGAA	-0.28%	+2.75%	+4.51%	-36.62%	65.74B
HALOZYME THERAPEUTICS, INC.	-3.40%	-2.51%	+17.01%	+37.36%	6.03B
YUHAN CORPORATION	-0.93%	-1.10%	+87.20%	+112.90%	6.11B
SK BIOPHARMACEUTICALS CO., LTD.	-3.23%	-3.98%	+10.76%	-7.23%	5.41B
BETTA PHARMACEUTICALS CO., LTD.	+0.73%	-2.56%	-6.46%	-34.19%	3.11B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+1.64%	+2.73%	+22.05%	+31.50%	2.29B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.32%	+0.38%	-34.87%	+28.20%	2.02B
SUPERNUS PHARMACEUTICALS, INC.	+0.30%	-0.81%	+39.06%	+27.55%	2.03B
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
Average	-0.57%	-0.55%	+15.46%	+15.08%	10.26B
Weighted average by Cap.	-0.54%	+1.05%	+10.18%	-16.32%

	2024 *	2025 *
Net sales	491B 3.22B 3.07B 2.85B 2.53B 4.55B 273B 5.06B 35.38B 13.1B 112B 12.1B 11.83B	498B 3.27B 3.12B 2.89B 2.56B 4.62B 277B 5.13B 35.88B 13.29B 114B 12.27B 12B
Net income	68.77B 451M 430M 399M 354M 638M 38.24B 708M 4.95B 1.83B 15.72B 1.69B 1.66B	71.63B 470M 448M 415M 368M 664M 39.83B 738M 5.16B 1.91B 16.38B 1.76B 1.73B
Net Debt	-317B -2.08B -1.98B -1.84B -1.63B -2.94B -176B -3.27B -22.86B -8.47B -72.57B -7.82B -7.65B	-354B -2.32B -2.22B -2.06B -1.82B -3.29B -197B -3.65B -25.53B -9.46B -81.04B -8.73B -8.54B